"How to" guide for pharmacist-led implementation of beta-lactam therapeutic drug monitoring in the critically ill

被引:8
作者
Ausman, Sara N. [1 ]
Moreland-Head, Lindsay M. [2 ]
Abu Saleh, Omar J. [3 ]
Jannetto, Paul G. [4 ]
Rivera, Christina W. [2 ]
Stevens, Ryan J. [2 ]
Wessel, Rebecca M. [5 ]
Wieruszewski, Patrick F. [2 ]
Barreto, Erin [2 ,6 ]
BLOOM Study Grp
机构
[1] Mayo Clin Hlth Syst, Dept Pharm, Eau Claire, WI USA
[2] Mayo Clin, Dept Pharm, Rochester, MN USA
[3] Mayo Clin, Div Publ Hlth Infect Dis & Occupat Med, Rochester, MN USA
[4] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[5] Mayo Clin, Strategy Dept, Rochester, MN USA
[6] Mayo Clin, Dept Pharm, 200 1st St SW, Rochester, MN 55905 USA
来源
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | 2023年 / 6卷 / 08期
基金
美国国家卫生研究院;
关键词
antibacterial agents; beta-lactams; critical illness; pharmacists; pharmacokinetics; therapeutic drug monitoring; MANAGEMENT; FACILITATORS; ANTIBIOTICS; MEROPENEM; BARRIERS; ICU;
D O I
10.1002/jac5.1819
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Beta-lactam therapeutic drug monitoring (TDM) can improve precision dosing and clinical outcomes in critically ill patients, but has not been implemented widely in the United States. Mayo Clinic recently implemented a beta-lactam TDM program. This single-center experience forms the basis of the manuscript which outlines practical considerations involved with beta-lactam TDM implementation, including the pharmacist's role as a leader. Our implementation effort focused on three primary domains. First, we aimed to ensure a supportive organizational infrastructure. Early leadership engagement by the pharmacist-led core team facilitated advocacy for the clinical need, allocation of resources, and assay development. Second, core clinical workflows were developed that addressed the preferred patient population for use, desirable pharmacokinetic and pharmacodynamic targets, and the preferred sampling strategy. Clinical tools to guide pharmacists in interpreting the results (e.g., pharmacokinetics calculator) and documenting decisions were developed. Third, stakeholders were offered repeated exposure to evidence and expertise to facilitate understanding and application of the new practice. This act of 'individual internalization' seems to be uniquely important to beta-lactam TDM implementation compared with the implementation of other antimicrobial TDM programs. Educational strategies and supportive materials that were developed were focused on providing substantive and varied information tailored to the stakeholders' role in the process. For pharmacists, this included both clinical and operational considerations. A continuous improvement plan to support management of the process was instituted to address necessary updates and changes that inevitably emerged. In summary, the described approach to implementation of a pharmacist-led beta-lactam TDM program could be used as a roadmap to aid other institutions that aim to develop such a program.
引用
收藏
页码:964 / 975
页数:12
相关论文
共 41 条
[1]   Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper# [J].
Abdul-Aziz, Mohd H. ;
Alffenaar, Jan-Willem C. ;
Bassetti, Matteo ;
Bracht, Hendrik ;
Dimopoulos, George ;
Marriott, Deborah ;
Neely, Michael N. ;
Paiva, Jose-Artur ;
Pea, Federico ;
Sjovall, Fredrik ;
Timsit, Jean F. ;
Udy, Andrew A. ;
Wicha, Sebastian G. ;
Zeitlinger, Markus ;
De Waele, Jan J. ;
Roberts, Jason A. .
INTENSIVE CARE MEDICINE, 2020, 46 (06) :1127-1153
[2]   Barriers and Facilitators in the Clinical Implementation of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: A Critical Review [J].
Abdulla, Alan ;
van den Broek, Puck ;
Ewoldt, Tim M. J. ;
Muller, Anouk E. ;
Endeman, Henrik ;
Koch, Birgit C. P. .
THERAPEUTIC DRUG MONITORING, 2022, 44 (01) :112-120
[3]   Applying Cefepime Population Pharmacokinetics to Critically Ill Patients Receiving Continuous Renal Replacement Therapy [J].
Al-Shaer, Mohammad H. ;
Maguigan, Kelly ;
Ashton, Jennifer ;
Venugopalan, Veena ;
Droege, Molly E. ;
Philpott, Carolyn D. ;
Droege, Christopher A. ;
Healy, Daniel P. ;
Mueller, Eric W. ;
Peloquin, Charles A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (01)
[4]  
Barreto EF., 2022, THER DRUG MONIT
[5]  
Barreto Erin F, 2021, Crit Care Explor, V3, pe0446, DOI 10.1097/CCE.0000000000000446
[6]  
Berry AV., 2022, Open Forum Infect Dis, V9, DOI [10.1093/ofid/ofac492.652, DOI 10.1093/OFID/OFAB466.1303, 10.1093/ofid/ofab466.1303, DOI 10.1093/OFID/OFAC492.652]
[7]   Pharmacokinetics of Meropenem in Critically Ill Patients With Severe Infections [J].
Binder, Lutz ;
Schwoerer, Harald ;
Hoppe, Sebastian ;
Streit, Frank ;
Neumann, Silke ;
Beckmann, Annett ;
Wachter, Rolf ;
Oellerich, Michael ;
Walson, Philip D. .
THERAPEUTIC DRUG MONITORING, 2013, 35 (01) :63-70
[8]   Stability and Validation of a High-Throughput LC-MS/MS Method for the Quantification of Cefepime, Meropenem, and Piperacillin and Tazobactam in Serum [J].
Bjergum, Matthew W. ;
Barreto, Erin F. ;
Scheetz, Marc H. ;
Rule, Andrew D. ;
Jannetto, Paul J. .
JOURNAL OF APPLIED LABORATORY MEDICINE, 2021, 6 (05) :1202-1212
[9]   Cefepime neurotoxicity: thresholds and risk factors. A retrospective cohort study [J].
Boschung-Pasquier, L. ;
Atkinson, A. ;
Kastner, L. K. ;
Banholzer, S. ;
Haschke, M. ;
Buetti, N. ;
Furrer, D., I ;
Hauser, C. ;
Jent, P. ;
Que, Y. A. ;
Furrer, H. ;
Flury, B. Babouee .
CLINICAL MICROBIOLOGY AND INFECTION, 2020, 26 (03) :333-339
[10]   Evaluation of β-lactam therapeutic drug monitoring among US health systems with postgraduate year 2 infectious diseases pharmacy residency programs [J].
Chen, Chieh ;
Seabury, Robert W. ;
Steele, Jeffrey M. ;
Parsels, Katie A. ;
Darko, William ;
Miller, Christopher D. ;
Kufel, Wesley D. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (15) :1273-1280